ImmuneRegen BioSciences Inks Strategic Collaboration With MPI Research

As per the agreement, MPI Research is expected to develop and perform preclinical, FDA-required safety studies and analytical research services in support of ImmuneRegen’s lead drug candidate, Homspera, which are expected to enable Phase 1 human clinical studies.

Michael Wilhelm, CEO of ImmuneRegen, said: “The signing of today’s agreement with MPI Research allows us to begin our FDA-required safety studies immediately. ImmuneRegen expects that the resulting studies will provide information necessary to support planned INDs for indications such as influenza, idiopathic pulmonary fibrosis, and cancer.

“We feel our visibility to potential new partners will only increase as we achieve the significant milestones set forth by our development team. This is a pivotal time for the company and we believe this relationship confirms management’s belief that our company is significantly undervalued.”

William Parfet, chairman and CEO of MPI Research, said: “ImmuneRegen and MPI Research are both innovative companies that, together, create a synergy that is important within today’s drug development industry. This collaboration reflects the flexible, solution-based mindset of each organization, allowing them to effectively leverage their respective strengths and resources.”